These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

569 related items for PubMed ID: 25936324

  • 1. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U, Milton M, Stoellner D, Rader D, Gordon B, Polk D, Waldmann E, Parhofer KG, Moriarty PM.
    Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
    [Abstract] [Full Text] [Related]

  • 2. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P, Stenman UH, Gylling H.
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [Abstract] [Full Text] [Related]

  • 3. How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.
    Hohenstein B, Tselmin S, Bornstein SR, Julius U.
    Atheroscler Suppl; 2017 Nov; 30():28-32. PubMed ID: 29096851
    [Abstract] [Full Text] [Related]

  • 4. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis.
    Tavori H, Giunzioni I, Linton MF, Fazio S.
    Circ Res; 2013 Dec 06; 113(12):1290-5. PubMed ID: 24122718
    [Abstract] [Full Text] [Related]

  • 5. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.
    Atheroscler Suppl; 2015 May 06; 18():154-62. PubMed ID: 25936320
    [Abstract] [Full Text] [Related]

  • 6. Actual situation of lipoprotein apheresis in Saxony in 2013.
    Emmrich U, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May 06; 18():215-25. PubMed ID: 25936329
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
    Schampera S, Fischer S, Weiss N, Julius U.
    Atheroscler Suppl; 2015 May 06; 18():209-14. PubMed ID: 25936328
    [Abstract] [Full Text] [Related]

  • 11. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K, Park BS, Kim YW, Vaziri ND.
    Am J Kidney Dis; 2014 Apr 06; 63(4):584-9. PubMed ID: 24315769
    [Abstract] [Full Text] [Related]

  • 12. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
    Groß E, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May 06; 18():226-32. PubMed ID: 25936330
    [Abstract] [Full Text] [Related]

  • 13. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP.
    Transl Res; 2012 Aug 06; 160(2):125-30. PubMed ID: 22683370
    [Abstract] [Full Text] [Related]

  • 14. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS.
    Circulation; 2013 Aug 27; 128(9):962-9. PubMed ID: 23884353
    [Abstract] [Full Text] [Related]

  • 15. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
    Schettler VJ, Muellendorff F, Schettler E, Platzer C, Norkauer S, Julius U, Neumann CL.
    Ther Apher Dial; 2019 Oct 27; 23(5):467-473. PubMed ID: 30663261
    [Abstract] [Full Text] [Related]

  • 16. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H, Burns TL, Hilleman DE.
    Cardiovasc Ther; 2014 Apr 27; 32(2):82-8. PubMed ID: 24354905
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y, Baudin B, Kelbousi S, Sakly M, Attia N.
    J Diabetes Complications; 2015 Apr 27; 29(8):1165-70. PubMed ID: 26412029
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
    Julius U, Tselmin S, Schatz U, Fischer S, Birkenfeld AL, Bornstein SR.
    Atheroscler Suppl; 2019 Dec 27; 40():1-7. PubMed ID: 31818437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.